Multiple endocrine neoplasia type 2 natural history: Difference between revisions
Line 43: | Line 43: | ||
:* Sex of the [[patient]] | :* Sex of the [[patient]] | ||
:* [[Calcitonin]] doubling time | :* [[Calcitonin]] doubling time | ||
* The following table depicts the stage dependent prognosis of medullary thyroid cancer.<ref>Thyroid cancer: Stage and prognosis. American association of endocrine surgeons (30.10.2015). http://endocrinediseases.org/thyroid/cancer_prognosis.shtml Accessed on October, 30, 2015</ref> | * The following table depicts the stage dependent prognosis of medullary thyroid cancer.<ref>Thyroid cancer: Stage and prognosis. American association of endocrine surgeons (30.10.2015). http://endocrinediseases.org/thyroid/cancer_prognosis.shtml Accessed on October, 30, 2015</ref><ref name="RomanLin2006">{{cite journal|last1=Roman|first1=Sanziana|last2=Lin|first2=Rong|last3=Sosa|first3=Julie Ann|title=Prognosis of medullary thyroid carcinoma|journal=Cancer|volume=107|issue=9|year=2006|pages=2134–2142|issn=0008543X|doi=10.1002/cncr.22244}}</ref> | ||
<br> | <br> |
Latest revision as of 14:21, 26 June 2019
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 natural history On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 natural history |
Multiple endocrine neoplasia type 2 natural history in the news |
Blogs on Multiple endocrine neoplasia type 2 natural history |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Multiple endocrine neoplasia type 2 has a variable natural history. Life threatening complications of multiple endocrine neoplasia type 2 include malignant hypertension, megacolon, and metastasis. Prognosis of multiple endocrine neoplasia type 2 is mainly related to the stage-dependent prognosis of medullary thyroid cancer.
Natural History
Multiple endocrine neoplasia type 2 has a variable natural history. Specific c-RET mutations, are associated to peculiar clinical phenotypes and thus to different courses of the disease. Multiple endocrine neoplasia type 2 can vary from a dormant type after the surgical removal of medullary thyroid carcinoma to a rapidly progressive one with metastatic complications resulting in death.[1]
Complications
- Common complications of multiple endocrine neoplasia type 2 include the following:[2]
Systemic Complications
Endocrine Complications
Genitourinary System Complications
Gastrointestinal System Complications
- Obstruction
- Infection
- Stricture
- Fistula
- Constipation
- Fecal incontinence
- Diverticulum
- Gastrointestinal ganglioneuromatosis
- Megacolon
- Colitis
Prognosis
- Prognosis of multiple endocrine neoplasia type 2 is mainly related to the stage-dependent prognosis of medullary thyroid cancer indicating the necessity of a complete thyroid surgery for index cases with medullary thyroid cancer and the early thyroidectomy for screened at risk subjects.[3]
- The 10 year survival of medullary thyroid cancer of multiple endocrine neoplasia type 2 is 61-76%.[4]
- Multiple endocrine neoplasia type 2A has a better prognosis among the tumors of multiple endocrine neoplasia. Specific c-RET mutations, in fact, are associated to peculiar clinical phenotypes and thus to different course and prognosis of the disease. The following factors influencing survival rate of medullary thyroid carcinoma.
Stage | Prognosis |
---|---|
Stage 1 | Best Prognosis and low chance of recurrence |
Stage 2 | Good Prognosis and low chance of recurrence |
Stage 3 | Bad Prognosis and high chance of recurrence |
Stage 4 | Bad Prognosis and high chance of recurrence |
References
- ↑ Marini, Francesca; Falchetti, Alberto; Del Monte, Francesca; Carbonell Sala, Silvia; Tognarini, Isabella; Luzi, Ettore; Brandi, Maria (2006). Orphanet Journal of Rare Diseases. 1 (1): 45. doi:10.1186/1750-1172-1-45. ISSN 1750-1172. Missing or empty
|title=
(help) - ↑ Cohen MS, Phay JE, Albinson C, DeBenedetti MK, Skinner MA, Lairmore TC; et al. (2002). "Gastrointestinal manifestations of multiple endocrine neoplasia type 2". Ann Surg. 235 (5): 648–54, discussion 654-5. PMC 1422490. PMID 11981210.
- ↑ Raue, Friedhelm; Frank-Raue, Karin (2018). "Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma". Journal of the Endocrine Society. 2 (8): 933–943. doi:10.1210/js.2018-00178. ISSN 2472-1972.
- ↑ Raue, Friedhelm; Frank-Raue, Karin (2015). "Risk-stratified follow-up of patients with medullary thyroid carcinoma". International Journal of Endocrine Oncology. 2 (4): 249–252. doi:10.2217/ije.15.23. ISSN 2045-0869.
- ↑ Thyroid cancer: Stage and prognosis. American association of endocrine surgeons (30.10.2015). http://endocrinediseases.org/thyroid/cancer_prognosis.shtml Accessed on October, 30, 2015
- ↑ Roman, Sanziana; Lin, Rong; Sosa, Julie Ann (2006). "Prognosis of medullary thyroid carcinoma". Cancer. 107 (9): 2134–2142. doi:10.1002/cncr.22244. ISSN 0008-543X.